新视Neuromyelitis复发急性严重程度量表(P5.249)

文摘

摘要目的:开发和验证一个客观的规模代表程度的神经功能障碍的急性复发neuromyelitis视。背景:Neuromyelitis视(动)是一种自身免疫性疾病,中枢神经系统(CNS)不同于多发性硬化症(MS)。它的特点是反复发作的视神经炎(上)和纵向广泛的横向脊髓炎(LETM),这通常导致增量与事件相关的残疾。残疾通常被评为使用扩展残疾严重程度量表(eds)为女士开发试验。然而,eds视力和有限的变化不敏感的患者不能走路。设计/方法:我们设计了一个34分急性复发严重程度量表针对动,命名为动严重程度量表(nmos)重点领域最重要的影响包括1)视力,2)视觉领域,3)电机、4)感觉,5)肠和膀胱、6)脑干功能。我们询问了17个国际专家动审查记录20急性动招生约翰霍普金斯医院评估两分的nmos的可靠性和准确性。结果:nmos基于eds,但修改增加对视力和视觉领域。运动,感觉膀胱和肠/分数稍微修改,脑干分数改为关注NMO-specific postrema和间脑的攻击。nmos正在进行验证;两分的计算可靠性用斯皮尔曼等级相关系数和nmos将分析内容和预测效度。结论:nmos是未来新NMO-specific残疾量表的临床试验。研究支持:Guthy杰克逊慈善基金会

披露:Acorda疗法;赛诺菲;Viropharma有限公司;NeuralStem公司;夏尔/ Abvie;博士TerumoBCT粉没有披露。Jarius博士收到拜耳医疗和默克公司Serono研究支持。保罗医生已收到个人活动与补偿Teva神经科学,赛诺菲-安万特制药、拜耳先灵葆雅制药公司,默克公司Serono, Idec,落实和诺华。Aktas博士已经收到个人活动与拜耳补偿、Idec, Genzyme,诺华,Teva神经科学和落实的一个顾问。Broadley博士没有披露。Cabre博士已经收到个人活动与补偿Idec, EMD Serono,诺华。 Dr. Han has nothing to disclose. Dr. Jacob has nothing to disclose. Dr. John has received research support from Teva. Dr. Leite has nothing to disclose. Dr. Marignier has nothing to disclose. Dr. Nakashima has received personal compensation for activities with Bayer Schering Pharma, Novartis, and Biogen Idec. Dr. Nakashima has received research support from Mitsubishi Chemical Corporation. Dr. Palace has received personal compensation for activities with Novartis and Merck Serono. Dr. Schippling has received personal compensation for activities with Novartis. Dr. Schippling has received research support from Bayer Schering and Biogen Idec. Dr. Traboulsee has received personal compensation for activities with Roche Diagnostics Corporation, EMD Serono, Teva Neuroscience, and Biogen Idec, Novartis, and Genzyme Corporation. Dr. Weinshenker has received personal compensation for activities with Novartis, Biogen Idec, and Mitsubishi Pharmaceuticals, MedImmune Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical, and Novartis. Dr. Weinshenker has received royalty pay Dr. Wingerchuk has received personal compensation for activities with Medimmune, Alexion, and Chugai. Dr. Wingerchuk has received research support from Alexion and TerumoBCT.